W e evaluated the effects of two thiazolidinediones (TZDs), the potent PPARγ agonist rosiglitazone currently being used to treat diabetes, and a structurally similar experimental compound that is a poor PPARγ agonist, in a non-diabetic, established hypertension model with continuous measurement of blood pressure by telemetry. Hypertension was induced in male Dahl saltsensitive rats by a three-week pre-treatment with 4% salt before initiation of treatment. Fasting blood samples were taken for analysis of a biomarker panel to assess metabolic, anti-inflammatory and antioxidant activity of the treatments. Both TZDs significantly reduced both systolic and diastolic blood pressure. When used at the maximally effective doses established for metabolic improvement, both compounds produced equivalent reduction in lipids and elevation of adiponectin, yet the poorer PPARγ agonist produced significantly greater reductions in blood pressure. Neither compound had a significant effect on circulating glucose or insulin in this animal model.
Introduction
Thiazolidinediones (TZDs) are used to treat type 2 diabetes because of their efficacy in controlling blood glucose secondary to enhancing insulin action through a mechanism(s) that is yet to be completely elucidated. [1] [2] [3] [4] [5] Interestingly, a substantial number of studies have shown that these compounds are also capable of a rich array of beneficial effects, including reductions of blood pressure in animal models and humans. [6] [7] [8] [9] [10] Previous evaluations of blood pressure with these compounds have depended on indirect means. It is not clear whether the pleiotropic pharmacology of the TZDs, including the apparent antihypertensive effect, is dependent on improved insulin signalling in insulin-resistant states or whether there is any correlation between metabolic and antihypertensive pharmacology. 9, 10 These questions have important implications for the utility of this class of compounds and the development of future compounds with this (these) mechanism(s) of action.
Insulin-sensitising TZDs are generally considered to work as agonists of the nuclear receptor peroxisome proliferatoractivated receptor (PPAR)γ. 11, 12 Thus, the beneficial effects on metabolic parameters are thought to occur secondary to changes in gene expression following direct activation of this nuclear receptor. However, the pharmacology of TZDs remains intact in tissue-specific PPARγ knockout mice to varying extents, suggesting that other factors may be involved. [13] [14] [15] [16] In addition to PPARγ interaction, TZDs also bind to the mitochondrial membrane, an interaction which may involve a recently described protein named mitoNEET, 17 and TZDs have effects on mitochondrial function that may play an important role in their overall pharmacology. 18 Thus, a combination of factors may determine the pharmacology exerted by individual compounds. Furthermore, it has recently been suggested that PPARγ-driven expression of epithelial sodium channels (ENaC) in the collecting ducts contributes to the volume expansion associated with TZD use, an effect that would mitigate against a reduction in blood pressure, particularly in a salt-fed model. 19, 20 Here we ask whether two similar compounds with different abilities to activate PPARγ can inhibit the progression of established hypertension in Dahl salt-sensitive rats on a high-salt diet. Rosiglitazone, a compound currently utilised for treatment of type 2 diabetes, is a full agonist of PPARγ, 21 whereas the experimental compound PNU-91325 is a weaker agonist both in vitro and in vivo. 22, 23 Direct blood pressure and heart rate were measured by telemetry.
Materials and methods

Experimental protocols
Male Dahl SS/JrHsd rats (six weeks old) were obtained from Harlan Laboratories and implanted with radiotelemetry transmitters (Data Sciences, International, Roseville, MN). The transmitters were implanted into the abdominal aorta via a 2.5 to 3 cm laparotomy under aseptic conditions. Following surgery, animals were individually housed and allowed five to seven days to recover prior to experimentation. During this period, animals were allowed regular rodent food and tap water ad libitum. After the recovery period, animals were placed on specialised chow containing 4% NaCl for three weeks to establish salt-induced hypertension.
During the last week of the pre-treatment period, rats were divided into four groups with similar hypertension based on 24-hour averages. These groups were then dosed with vehicle (1% sodium carboxymethylcellulose/0.01% Tween 20), amlodipine (3 mg/kg/day, PO), rosiglitazone (20 mg/kg/day, PO) or PNU-91325 (40 mg/kg/day, PO) for up to three weeks to evaluate the potential for reversal of hypertension in the continued presence of the salt challenge. These doses were chosen based on ancillary experiments that indicated that these doses of rosiglitazone and PNU-91325 produce maximum metabolic effects in various rat models. Amlodipine was used as a positive control for the antihypertensive action. During the experimental periods, the high NaCl food and water were available ad libitum. Systolic pressure, diastolic pressure and heart rate were recorded and averaged every 15 minutes. A 24-hour urine collection was made in metabolic cages 15 days into the treatment. All animals were fasted for six hours prior to sacrifice. They were anaesthetised with CO 2 , then blood was taken from the abdominal aorta and collected into heparincoated tubes for separation of plasma. Distal colon and kidney samples were taken for measurement of sodium channel expression.
Pharmacokinetics
A satellite group of male Dahl SS/JRHsd rats (eight weeks old) ORIGINAL ARTICLE was used for pharmacokinetics (PK) analysis. Animals were bled retro-orbitally to measure compound levels. Whole blood samples were collected at 0.5, 1, 2, 4, 8 and 24 hours and serum was obtained by centrifugation.
Statistical treatment of data
Statistical evaluation of blood pressure utilised a sin/cos model for the fixed time period of 24 hours to model and subtraction of the effects of the circadian rhythm for each animal. The residuals (from the subtraction) were then analyzed using a one-way analysis of variance with planned comparisons to the vehicle group. Statistical significance for the end points in tables 1 and 2 was determined using a twotailed, homoscedastic student's t-test.
Analytical procedures
Plasma was assayed for glucose, triglycerides, free fatty acids, plasminogen activator-inhibitor (PAI), thiobarbituric acid reactive substances (TBARS), interleukin-8 (IL-8) and adiponectin by MDS pharmaceuticals (Bothell, WA). Plasma insulin was measured in-house by immunoassay (Linco, St. Louis, MO). Real-Time RT-PCR Analysis reagents, software and equipment were purchased from Applied Biosystems. Taqman reactions were performed in triplicate using One-
Step RT-PCR Master Mix Reagents with the ABI PRISM®7900 Sequence Detection System. Gene expression was calculated using the comparative CT method. All procedures in this study were approved and conducted in compliance with the Animal Welfare Act Regulations (9 CFR Parts 1, 2 and 3) and the 'Guide for the Care and Use of Laboratory Animals' (ILAR, 1996) , and with all internal company policies and guidelines.
Results
PNU-91325 and rosiglitazone exert equivalent metabolic effects
Once-daily doses of PNU-91325 and rosiglitazone were chosen that were known to produce maximum pharmacological effects with respect to metabolic parameters in other animal models. As expected, these doses of both PNU-91325 and rosiglitazone produced equivalent decreases in circulating triglycerides and free fatty acids (FFA), while amlodipine, chosen as a positive control for blood pressurelowering, had no effect on circulating lipids (table 1) .
Adiponectin is a putative hormone released from adipocytes that may mediate some of the insulin sensitising of the thiazolidinediones. 24 TZDs elevate circulating levels of adiponectin in many animal models and in man. 25, 26 As expected for the doses chosen, both PNU-91325 and rosiglitazone produced an equivalent 250% increase in plasma adiponectin concentration. In contrast, the calcium channel blocker amlodipine did not increase circulating adiponectin (table 1) .
The pleiotropic actions ascribed to thiazolidinediones include both anti-inflammatory actions and protection against oxidative damage. 4, 5 As shown in table 1, both PNU-91325 and rosiglitazone decreased the circulating concentration of the chemokine IL-8, a marker of inflammation. The thiazolidinediones also decreased circulating TBARS, a marker for lipid peroxidation and oxidative stress. Again, and as expected, these parameters were not significantly affected by amlodipine treatment. Elevation of circulating plasminogen activator inhibitor-1 (PAI-1) is thought to contribute to the pro-thrombotic state and reduction of PAI-1 may be of benefit in preventing cardiovascular disease. Both PNU-91325 and amlodipine reduced circulating levels of PAI-1. This reduction may be related to the reduction in blood pressure produced by these agents (see below).
Thiazolidinediones lower glucose in hyperglycaemic, diabetic animal models but they do not affect circulating glucose in normoglycaemic animals. 5 As expected, none of the treatments affected fasting glucose levels in the Dahl rats (table 1) . Under these conditions in these animals a significant change in circulating concentrations of fasting insulin did not take place (table 1). All of the drug treatments increased the body weight gain over the study period as compared to the vehicle group (table 1) . This may reflect an improvement in the overall health of these severely hypertensive rats.
PNU-91325, rosiglitazone and amlodipine lower systolic and diastolic blood pressure in the hypertensive Dahl-SS rat
Blood pressure increased progressively when the Dahl rats were placed on a 4% salt diet, and it continued to increase throughout the study in the vehicle-treated rats. The values for the last three days of the three-week lead-in period on the high-salt diet are shown in figure 1 for systolic blood pressure (upper panel), diastolic blood pressure (centre panel) and heart rate (lower panel). At the time of the leadin period, systolic blood pressure averaged 171 mmHg. At the point of the arrows, groups equalized for blood pressure were given a single oral dose of vehicle (black), rosiglitazone (blue), PNU-91325 (red) or amlodipine (green) as a oncedaily dose that continued throughout the remainder of the study. Blood pressure continued to rise in the vehicle-treated rats. Treatment with all three compounds produced a significant decrease in blood pressure compared to the vehicletreated rats by the first day after treatment (p<0.001). All of the treatments decreased both systolic and diastolic pressure and these decreases were maintained compared to the vehicle-treated rats throughout the three weeks of the study (p<0.001). The decreases in both systolic and diastolic pressure produced by PNU-91325 were significantly greater than those produced by rosiglitazone under these conditions for all days of treatment (p<0.001), but not as great as the decreases in blood pressure produced by the positive control, amlodipine.
Although the effects of rosiglitazone and PNU-91325 on blood pressure differed only quantitatively, there was a qualitative difference in the effects on heart rate. As expected, the decrease in blood pressure produced an immediate compensatory increase in heart rate ( figure 1, lower panel) with all treatments. The immediate increase was proportional to the decrease in blood pressure for all treatments during the first week of treatment. However, after the first week of treatment with PNU-91325, although blood pressure remained reduced versus the vehicle and rosiglitazone groups, heart rate decreased relative to all groups in spite of the continued high sodium intake (p<0.001). From day 12 through to completion of the experiment, the heart rate of animals receiving PNU-91325 averaged 14 beats per minute less than those in the vehicle group (p<0.000001) and nine beats per minute less than those receiving rosiglitazone (p<0.000001). Thus, in spite of the fact that these doses of the two TZDs have similar metabolic effects on lipids and adiponectin levels, PNU-91325 produced a significantly larger decrease in blood pressure and heart rate under these conditions than rosiglitazone. ORIGINAL ARTICLE
Figure 1. Daily 24-hour summary of parameters measured by telemetry. (a) Systolic blood pressure; (b) diastolic blood pressure; (c) heart rate
Effects of thiazolidinediones and amlodipine on blood pressure and heart rate. Salt-sensitive Dahl rats were placed on a 4% NaCl diet for three weeks and then continued on that diet for an additional three weeks while being dosed daily by oral gavage with vehicle (black circles), rosiglitazone (purple squares), PNU-91325 (yellow diamonds) or amlodipine (light purple diamonds). Blood pressure and heart rate were measured continuously by telemetry and averages were recorded every 15 minutes throughout the pre-treatment and treatment periods. Data are presented as the mean and SEM for 9-10 rats/group for 24-hour averages, as described in the text. The data are given for the last three days of the pretreatment period and as daily averages after beginning of oral dosing (at arrow) Figure 2 shows the hourly change in systolic blood pressure following the initial dose of the treatments from the protocol shown in figure 1 . For comparison, the two-hourly averages before the initial dose as well as the remainder of the hourly measurements are shown. Amlodipine treatment lowered blood pressure within one hour of treatment and blood pressure remained lower than the pre-dose blood pressure and the vehicle control for most of the day. In contrast, the TZDs did not produce a measurable effect on blood pressure until three hours after dosing; however, this effect was then maintained throughout the 24-hour period (figure 2a).
To determine whether the pharmacokinetics of the TZD molecules tested here might add to the understanding of this pharmacological effect, the circulating concentrations of PNU-91325, its major alcohol metabolite and rosiglitazone were measured in an additional group of rats treated in the same fashion as those shown in figure 2a . Rosiglitazone is also known to give rise to considerable concentrations of metabolites 27 that may contribute to its pharmacological effects (see below) but they were not measured in these studies. These data show that while the concentrations of PNU-91325 are lower than rosiglitazone under these conditions, the major metabolite of PNU-91325 circulates throughout the day at concentrations that may be expected to have direct cellular effects that are both PPARγ-dependent and -independent, 22, 23 which may contribute to the sustained antihypertensive pharmacology seen in this animal model.
We evaluated whether there might be different effects of these treatments on the expression of sodium channels that could contribute to blood pressure regulation. Table 2 shows the relative expression of three epithelial sodium channels in the kidney and the distal colon. Although none of the treatments significantly affected the expression of these channels in samples from the kidney, both TZDs produced a significant decrease in the expression of ENaCβ‚ and ENaCγ (80-89%) in the distal colon. It is possible that there may be selective effects on the expression of these channels in parts of the kidney, 19 but we did not observe a significant effect on urinary volume or salt excretion in these studies (table 3) . Salt content of the stools was not measured.
Discussion
Several clinical studies have shown that both of the TZDs currently utilised for treatment of diabetes can produce some lowering of blood pressure in clinical practice. 7, 8 There is also a collection of preclinical data showing that a number of these insulin-sensitising compounds may lower blood pressure in animals that may or may not be "insulin-resistant." 9,10 However, many of these studies have used indirect measurements of blood pressure and they generally show prevention of the development of hypertension rather than the treatment of established hypertension. It is also not clear whether any decreases in blood pressure that do occur are in fact related to improvement or changes in metabolic parameters.
These studies compare the effects of two structurally similar TZD insulin-sensitising agents, rosiglitazone, an agonist of the nuclear receptor PPARγ currently utilised as an antidia-betic agent, and PNU-91325, an experimental compound that is a weaker agonist. Doses were picked from ancillary studies such that maximum and similar metabolic effects would occur. Blood pressure and heart rate were measured directly by telemetry.
The current data prove conclusively that these two TZDs significantly reduce blood pressure in a rat model of hypertension that is not diabetic. Both systolic and diastolic pressure are reduced, and the reduction does not involve measurable changes in the circulating concentrations of glucose or insulin. Although the two structurally similar TZDs produced equivalent reductions in circulating lipids and elevations of circulating adiponectin, the effects on blood pressure and heart rate were not equivalent. The experimental compound PNU-91325, which is approximately 100 times less potent an activator of PPARγ and exerts little PPARγ activation in vivo, 22 produced approximately twice the reduction of blood pressure compared to rosiglitazone under these conditions. The reduction in blood pressure occurred without a sustained increase in heart rate and, in fact, one week's treatment resulted in a decreased heart rate. These results suggest that further studies should be conducted to determine whether there might be an improvement in cardiac function upon treatment with such compounds under these conditions.
Given the pharmacology of the TZDs and the reduction of blood pressure that occurred in this model, some protection of renal function under these conditions might be expected. However, renal albumin excretion was high (116-140 mg/day) and was unaffected by these treatments. This may reflect the degree of damage that occurred before the initiation of drug treatment (i.e. there was a three-week lead-in on the high-salt diet) and different results might have been obtained if the drug treatments had been started earlier or extended for a longer time.
The mechanism(s) by which the TZDs lowered blood pressure in this model is (are) unknown at the current time. One possibility for the reduced antihypertensive action of the full PPARγ agonist rosiglitazone compared to the weaker agonist PNU-91325 might be limitation of sodium excretion. Recent evidence suggests that fluid retention with some TZDs is mediated in part through PPARγ-driven expression of ENaCγ. 19, 20 It is not clear that such an event could have occurred under these conditions, however. In fact rosiglitazone produced a smaller increase in body weight, which would be expected to occur with fluid retention, than either PNU-91325 or amlodipine (table 1) , and haematocrit measurements did not differ among the treatment groups (table  1) . Moreover, although both TZDs lowered ENaCβ‚ and ENaCγ expression in the distal colon, there were no measurable changes in expression in the kidney under these conditions (table 2) and no significant change in urinary excretion of sodium (table 3) . Thus, it seems likely that the reduction in blood pressure produced in this model may derive from effects on vascular peripheral resistance instead (see below).
The greater blood pressure effect of PNU-91325 under these conditions could be explained by pharmacokinetic differences between the compounds that may otherwise work through the same mechanism(s). The active metabolite of PNU-91325 circulated at high μM concentrations throughout the dosing interval, while rosiglitazone exposure was undetectable for approximately a third of the 24-hour dosing period. It is important to note, as discussed above however, that we did not measure the rosiglitazone metabolites in this study. In any event, the compounds had comparable effects on metabolic end points but differed in their ability to lower blood pressure and heart rate. Therefore, metabolic improvements are either disconnected from blood pressure mechanistically or the pharmacokinetic-pharmacodynamic relationship for the metabolic versus blood pressure end points differs under the conditions tested.
A brief speculation about the potential mechanisms responsible for this pharmacology is warranted. It has previously been noted that TZDs activate key redox-sensitive enzyme systems such as AKT and AMPK directly. 22 Furthermore, redox-sensitive mechanisms drive an inflammatory response initiated by free fatty acids that can limit vasodilatory mechanisms. 28 Thus, one possibility is that vascular inflammatory events, fuelled by oxidative metabolism, favour vasoconstriction, e.g. secondary to a metabolic inflammation, and this may be prevented by effects of the TZDs or their metabolites to alter the activation state of key kinases and phosphatases. 29 Consistent with this hypothesis, Bagi et al. 30 have shown that rosiglitazone could promote dilation of coronary arterioles by increasing the availability of nitric oxide secondary to reducing local oxidative stress in a diabetic mouse model. It is possible that these effects may occur secondary to a mitochondrial action. Wiley et al. 31 have recently shown that the mitochondrial protein crosslinked by a thiazolidinedione probe 17 may play a significant role in the regulation of oxidative metabolism.
Regardless of the mechanisms involved, this study shows that TZDs have a significant effect on blood pressure in a salt-sensitive model of hypertension, that the effectiveness in this regard may differ significantly between TZDs, and that the antihypertensive effect is not simply correlated to the overall metabolic effects of the compounds. The ability of some TZDs to reverse many of the major factors leading to increased risk of cardiovascular disease, including insulin resistance, dyslipidaemia, inflammation and blood pressure, suggests that an optimal compound might find a more general therapeutic utility in the treatment/prevention of cardiovascular disease. 
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